{
    "organizations": [],
    "uuid": "3e6d0e16468ac7ed06e0648bfde0d0c5c603a8e1",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/12/globe-newswire-dova-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2017-financial-results-on-february-15-2018.html",
    "ord_in_thread": 0,
    "title": "Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 15, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "DURHAM, N.C., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, February 15, 2018 at 4:30 p.m. EST to discuss fourth quarter and full year 2017 financial results and recent operational highlights. A question-and-answer session will follow Dova's remarks.\nTo participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.\nA live audio webcast of the call will also be available via the \"Investor Relations\" page of the Dova website, www.dova.com . Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.\nAbout Dova Pharmaceuticals, Inc.\nDova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dovaâ€™s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been accepted for priority review by FDA for this initial indication with a PDUFA goal date of May 21, 2018.\nContacts\nMark W. Hahn\nChief Financial Officer\n(919) 338-7936\nmhahn@dova.com\nWestwicke Partners\nJohn Woolford\n(443) 213-0506\njohn.woolford@westwicke.com\nSource:Dova Pharmaceuticals, Inc.",
    "published": "2018-02-13T00:15:00.000+02:00",
    "crawled": "2018-02-13T01:00:17.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "durham",
        "globe",
        "newswire",
        "dova",
        "pharmaceutical",
        "nasdaq",
        "dova",
        "host",
        "conference",
        "call",
        "thursday",
        "february",
        "est",
        "discus",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "recent",
        "operational",
        "highlight",
        "session",
        "follow",
        "dova",
        "remark",
        "participate",
        "live",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "provide",
        "conference",
        "id",
        "five",
        "minute",
        "start",
        "call",
        "live",
        "audio",
        "webcast",
        "call",
        "also",
        "available",
        "via",
        "investor",
        "relation",
        "page",
        "dova",
        "website",
        "please",
        "log",
        "dova",
        "website",
        "approximately",
        "minute",
        "scheduled",
        "start",
        "time",
        "replay",
        "webcast",
        "archived",
        "dova",
        "website",
        "day",
        "following",
        "call",
        "dova",
        "pharmaceutical",
        "dova",
        "pharmaceutical",
        "company",
        "focused",
        "acquiring",
        "developing",
        "commercializing",
        "drug",
        "candidate",
        "rare",
        "disease",
        "high",
        "unmet",
        "need",
        "initial",
        "focus",
        "addressing",
        "thrombocytopenia",
        "dova",
        "lead",
        "drug",
        "candidate",
        "avatrombopag",
        "successfully",
        "completed",
        "two",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "treatment",
        "thrombocytopenia",
        "patient",
        "cld",
        "scheduled",
        "undergo",
        "procedure",
        "nda",
        "accepted",
        "priority",
        "review",
        "fda",
        "initial",
        "indication",
        "pdufa",
        "goal",
        "date",
        "may",
        "contact",
        "mark",
        "hahn",
        "chief",
        "financial",
        "officer",
        "mhahn",
        "westwicke",
        "partner",
        "john",
        "woolford",
        "source",
        "dova",
        "pharmaceutical",
        "inc"
    ]
}